18 and older, any sex, with Tobacco Dependence. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Treatment SatisfactionPrimary· 60 days
Rating of satisfaction with quitline services on a 6-point scale collected via follow-up survey. Five questions were internally developed to determine satisfaction with the quitline services provided where low numbers (1-3) mean dissatisfaction and high numbers (4-6) mean satisfaction. Participants that reported a score of 4 (somewhat satisfied) or more are represented in the data table.
Group
Value
95% CI
Quitline Treatment as Usual (TAU)
38
Quitline TAU Plus Remote CO Monitoring
44
Quitline TAU Plus Incentivized Remote CO Monitoring
56
Treatment EngagementPrimary· 60 days
Number of quitline calls each participant engages in, collected via clinical record system.
Group
Value
95% CI
Quitline Treatment as Usual (TAU)
2.2
± 1.4
Quitline TAU Plus Remote CO Monitoring
2.3
± 1.6
Quitline TAU Plus Incentivized Remote CO Monitoring
2.7
± 1.9
Self-reported Tobacco AbstinencePrimary· 60 days
7 day point prevalence abstinence from all combustible tobacco collected via follow-up survey
Group
Value
95% CI
Quitline Treatment as Usual (TAU)
15
Quitline TAU Plus Remote CO Monitoring
18
Quitline TAU Plus Incentivized Remote CO Monitoring
25
Biochemically Verified Tobacco AbstinenceSecondary· 60 days
CO monitor reading 60 days post randomization (must be 7ppm or less to be considered abstinent) collected via smartphone app
Group
Value
95% CI
Quitline Treatment as Usual (TAU)
6
Quitline TAU Plus Remote CO Monitoring
14
Quitline TAU Plus Incentivized Remote CO Monitoring
20
Engagement With CO MonitorSecondary· 60 days
Number of times remote CO monitor is used collected via smartphone app.
Group
Value
95% CI
Quitline Treatment as Usual (TAU)
7.7
± 7.3
Quitline TAU Plus Remote CO Monitoring
54.8
± 49.6
Quitline TAU Plus Incentivized Remote CO Monitoring
80.9
± 48.5
Satisfaction With CO MonitorSecondary· 60 days
Satisfaction with CO monitor measures on a 6-point scale collected via follow-up survey. Five questions were internally developed to determine satisfaction with the CO monitor device and app where low numbers (1-3) mean dissatisfaction and high numbers (4-6) mean satisfaction. Participants that reported a score of 4 (somewhat satisfied) or more are represented in the data table.
Group
Value
95% CI
Quitline Treatment as Usual (TAU)
30
Quitline TAU Plus Remote CO Monitoring
38
Quitline TAU Plus Incentivized Remote CO Monitoring
51
Sponsor's own description
The present study is a 3-arm randomized controlled pilot study. Participants who call the Maryland Tobacco Quitline and are eligible for study participation are randomized to receive quitline tobacco cessation treatment as usual (TAU), TAU plus remote carbon monoxide (CO) monitoring via smartphone app, or TAU plus remote carbon monoxide monitoring plus incentives vis smartphone app. The investigators hypothesize that remote CO monitoring will be feasible and acceptable to deliver in the quitline setting, will increase treatment engagement, and will increase tobacco cessation and treatment satisfaction rates.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Consumer Wellness Solutions
Last refreshed: 28 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05327660.